Download MendeleyPotent and selective aminopyrimidine-based B-raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Mathieu, S., Gradl, S.N., Ren, L., Wen, Z., Aliagas, I., Gunzner-Toste, J., Lee, W., Pulk, R., Zhao, G., Alicke, B., Boggs, J.W., Buckmelter, A.J., Choo, E.F., Dinkel, V., Gloor, S.L., Gould, S.E., Hansen, J.D., Hastings, G., Hatzivassiliou, G., Laird, E.R., Moreno, D., Ran, Y., Voegtli, W.C., Wenglowsky, S., Grina, J., Rudolph, J.(2012) J Med Chem 55: 2869-2881
- PubMed: 22335519 Search on PubMed
- DOI: https://doi.org/10.1021/jm300016v
- Primary Citation Related Structures:
4EHE, 4EHG - PubMed Abstract:
Recent clinical data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-Raf(V600E) mutant melanoma. Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low solubility requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures. Through structure-based design, we discovered a new class of highly potent aminopyrimidine-based B-Raf inhibitors with improved solubility and pharmacokinetic profiles. The hinge binding moiety possesses a basic center imparting high solubility at gastric pH, addressing the dissolution limitation observed with our previous series. In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogues 32 and 35 (G945), molecules with desirable physicochemical properties, emerged as lead compounds with strong efficacy in a B-Raf(V600E) mutant mouse xenograft model. Synthesis, SAR, lead selection, and evaluation of key compounds in animal studies will be described.
- Genentech, Inc., 1 DNA Way, South San Francisco, California 94080-4990, United States.
Organizational Affiliation:
